Titlebook: Breast Disease; Management and Thera Adnan Aydiner,Abdullah Igci,Atilla Soran Book 2019Latest edition Springer Nature Switzerland AG 2019 b

調(diào)整

Rui Liu,Feilong Bao,Guanglai Gao,Yonghe Wange “oncoplastic breast surgery (OBS)” concept has come into consideration among breast surgeons in the last two decades. The aim of OBS is to make no compromise from oncologic principles for a better cosmetic result. The tumor cavity is filled with the remaining breast tissue (volume displacement tec

進(jìn)步

Research on Telegrapher Selectionaxilla can become negative in up to 60% of cases depending on tumor biology, and SLNB can be performed with a low false-negative rate either using the targeted (clip-seed) technique or in the classic fashion (lympho-blue dye). In patients with positive SLNB (with limited involvement) after neoadjuva

仲裁者

Haijing Song,Li Han,Hongjiao Wus with tamoxifen in premenopausal and postmenopausal women, lowering systemic estrogen levels with luteinizing hormone-releasing hormone agonists in premenopausal women, or blocking estrogen biosynthesis in nonovarian tissues with aromatase inhibitors in postmenopausal women.

Harrowing

Man-Machine-Environment System Engineeringgimen depends on the intrinsic subtype. Multigene expression array profiling is not always required for subtype definition after clinicopathological assessment. Young age, grade 3 disease, lymphovascular invasion, one to three positive nodes, and large tumor size are not adequate features to omit mo

drusen

Shengzhao Long,Balbir S. Dhillonnts with HER-2-positive early breast cancer. Thus, the monoclonal antibody trastuzumab has been approved as the first and only molecularly targeted agent for the adjuvant treatment of HER-2-positive breast cancer. Despite tremendous progress in the treatment of HER-2-positive breast cancer, many que

ALB

coddle

Chenming Li,Tianhao Wang,Yuhong ShenC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a

同義聯(lián)想法